Actively Recruiting
Comparing Siplizumab and Rabbit Anti-Thymocyte Globulin to Support Kidney Transplant Acceptance in Adults with End Stage Kidney Disease
Led by Nefro Avillion Clinical Development, LLC · Updated on 2026-11-03
120
Participants Needed
24
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating siplizumab, an anti-CD2 monoclonal antibody, compared to rabbit anti-thymocyte globulin rATG to prevent kidney transplant rejection in adults with end stage kidney disease. This phase 2b study focuses on safety, dosing, and effectiveness in helping the body accept a kidney transplant while participants also receive standard immunosuppressive therapy. The trial will enroll approximately 120 participants who need induction therapy for kidney transplantation. Participants will be randomly assigned to one of three groups two groups will receive different doses of siplizumab, and the third group will receive rATG. All participants will continue standard anti-rejection medicines before, during, and after transplant, including tacrolimus, mycophenolic acid, and corticosteroids. Premedications to reduce reaction risks and infection prevention treatments will also be given. The treatment period includes the transplant hospitalization and subsequent monitoring. Participants will provide medical and medication histories and undergo physical exams, vital sign checks, blood tests, and heart electrical activity monitoring ECG at the first visit and throughout the study. Safety assessments include viral monitoring and lab tests. Follow-up visits will continue for 12 months after transplant to monitor safety and transplant success. Researchers will measure adverse events, transplant rejection, graft function, and how the body responds to the study drugs.
CONDITIONS
Brief Title
A Study Comparing Siplizumab With Rabbit Anti-Thymocyte Globulin to Help the Body Accept a Kidney Transplant
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here